% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Reissig:275929,
      author       = {T. M. Reissig$^*$ and I. Tzianopoulos$^*$ and S.-T.
                      Liffers$^*$ and V. K. Rosery$^*$ and M. Guyot and S. Ting
                      and M. Wiesweg$^*$ and S. Kasper$^*$ and P. Meister and T.
                      Herold and H. H. Schmidt and B. Schumacher and D. Albers and
                      P. Markus and J. Treckmann and M. Schuler$^*$ and H.-U.
                      Schildhaus$^*$ and J. T. Siveke$^*$},
      title        = {{S}maller panel, similar results: genomic profiling and
                      molecularly informed therapy in pancreatic cancer.},
      journal      = {ESMO open},
      volume       = {8},
      number       = {3},
      issn         = {2059-7029},
      address      = {London},
      publisher    = {BMJ},
      reportid     = {DKFZ-2023-00917},
      pages        = {101539},
      year         = {2023},
      abstract     = {Pancreatic cancer has a dismal prognosis. One reason is
                      resistance to cytotoxic drugs. Molecularly matched therapies
                      might overcome this resistance but the best approach to
                      identify those patients who may benefit is unknown.
                      Therefore, we sought to evaluate a molecularly guided
                      treatment approach.We retrospectively analyzed the clinical
                      outcome and mutational status of patients with pancreatic
                      cancer who received molecular profiling at the West German
                      Cancer Center Essen from 2016 to 2021. We carried out a
                      47-gene DNA next-generation sequencing (NGS) panel.
                      Furthermore, we assessed microsatellite
                      instability-high/deficient mismatch repair (MSI-H/dMMR)
                      status and, sequentially and only in case of KRAS wild-type,
                      gene fusions via RNA-based NGS. Patient data and treatment
                      were retrieved from the electronic medical records.Of 190
                      included patients, 171 had pancreatic ductal adenocarcinoma
                      $(90\%).$ One hundred and three patients had stage IV
                      pancreatic cancer at diagnosis $(54\%).$ MMR analysis in 94
                      patients (94/190, $49.5\%)$ identified 3 patients with dMMR
                      (3/94, $3.2\%).$ Notably, we identified 32 patients with
                      KRAS wild-type status $(16.8\%).$ To identify driver
                      alterations in these patients, we conducted an RNA-based
                      fusion assay on 13 assessable samples and identified 5
                      potentially actionable fusions (5/13, $38.5\%).$ Overall, we
                      identified 34 patients with potentially actionable
                      alterations (34/190, $17.9\%).$ Of these 34 patients, 10
                      patients (10/34, $29.4\%)$ finally received at least one
                      molecularly targeted treatment and 4 patients had an
                      exceptional response (>9 months on treatment).Here, we show
                      that a small-sized gene panel can suffice to identify
                      relevant therapeutic options for pancreatic cancer patients.
                      Informally comparing with previous large-scale studies, this
                      approach yields a similar detection rate of actionable
                      targets. We propose molecular sequencing of pancreatic
                      cancer as standard of care to identify KRAS wild-type and
                      rare molecular subsets for targeted treatment strategies.},
      keywords     = {Archer (Other) / KRAS wild-type (Other) / NGS (Other) /
                      targeted sequencing (Other) / targeted therapy (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37148593},
      doi          = {10.1016/j.esmoop.2023.101539},
      url          = {https://inrepo02.dkfz.de/record/275929},
}